In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
List view / Grid view
Filter the results
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
A new imaging method called FLASH can provide a visualisation of several tissue types in a 3D format, its developers say.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
By targeting the mutated KRAS gene, researchers have developed an experimental vaccine that protected mice against a range of cancers.
The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
A protein called PPP1R1B has been revealed as a drug target for pancreatic cancer as it stopped the metastasis of tumours in mice.
Scientists identified a novel, highly specific drug target in the enzyme (sterol O-acyltransferase 1 (SOAT1)) cancer cells use to store cholesterol.
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
By targeting NHE7 transport proteins in pancreatic tumours, researchers caused the pH of cancer cells to become acidic, combatting the condition.
Researchers have demonstrated that cysteinase, a new drug compound, can starve pancreatic cells of cysteine supply, causing ferroptosis.
Scientists identify innate lymphoid cells (ILCs) as possible targets for immunotherapies as their activation makes murine pancreatic tumours sensitive to PD-1 checkpoint inhibitors.